liner regression analysis from 1,090 community-dwelling healthy subjects (HLT) who underwent frailty assessment. The gap of frailty values: [(estimated e actual)/estimated] was regarded as a frailty gap (%), and the total frailty gap was established by adding each frailty gap. We retrospectively compared total frailty gap between HLT and cancer patients. Total frailty gap <20% were classified non-frail, 20-100% were mild-frail, 100-170% were moderate-frail, and >170% were severe-frail. Independent factors that were significantly associated with overall survival in cancer patients were evaluated by multivariate regression analysis.
INTRODUCTION AND OBJECTIVES: An important reason for lower urinary tract symptoms (LUTS) in elderly men is Benign Prostatic
Hyperplasia (BPH). Erectile dysfunction (ED) also has a negative effect on quality of life (QoL) also a major problem at this age.
Dutasteride decreases the size of the prostate but has sexual problems, impotence as an adverse effect. These may be nullified with Tadalafil which used in the treatment of impotence and erectile dysfunction. It also has a proven beneficial effect in BPH.
AIM RESULTS: 'Dutasteride þ Tadalafil arm' (DþT) and 'Tadalafilþ placebo arm' (PþT), for only two parameters (IPSS-24 and Uroflow at 24 weeks UFR-24), (DþT) group showed statistically significant improvement over the (PþT) group (p<0.05).
For the rest of all the parameters, there was a statistically insignificant difference. Adverse effects were comparable.
CONCLUSIONS: Based on our study, combination therapy with daily Tadalafil and Finasteride/ Dutasteride is ideally suited for men with moderate to severe BPH-LUTS and a prostate volume >30 g.
In addition, men with coexisting ED will benefit from PDE5 inhibition.
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